Upgrade to SI Premium - Free Trial

Medicinova (MNOV)

1.27 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/14/26)

Latest Headlines

MediciNova receives patent allowance for glioblastoma combination therapy June 8, 2026 8:00 AM - StreetInsider MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment June 8, 2026 8:00 AM - StreetInsider MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) May 26, 2026 7:00 PM - StreetInsider Form 10-Q MEDICINOVA INC For: Mar 31 May 14, 2026 4:16 PM - SEC Filing Form ARS MEDICINOVA INC For: Dec 31 April 29, 2026 4:35 PM - SEC Filing Form DEFA14A MEDICINOVA INC April 29, 2026 4:33 PM - SEC Filing Form DEF 14A MEDICINOVA INC For: Jun 23 April 29, 2026 4:27 PM - SEC Filing New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation April 27, 2026 7:00 PM - Globe NewsWire Form PRER14A MEDICINOVA INC April 20, 2026 5:03 PM - SEC Filing Form PRE 14A MEDICINOVA INC For: Jun 23 April 17, 2026 4:57 PM - SEC Filing Maxim Group Resumes MediciNova (MNOV) at Buy, PT $6 March 23, 2026 7:27 AM - StreetInsider MediciNova to Participate at the 38th Annual ROTH Conference March 16, 2026 7:00 AM - StreetInsider H.C. Wainwright Starts MediciNova (MNOV) at Buy March 16, 2026 6:07 AM - StreetInsider Full Article List